Vermillion gets new CEO
This article was originally published in Clinica
Executive Summary
Women's health diagnostics specialist Vermillion has appointed Thomas McLain president and CEO, replacing Bruce Huebner, who was heading up the company on an interim basis. Mr Huebner will remain a director of the firm and help with the transition. The appointment comes almost a year after former CEO Gail Page announced she was leaving Vermillion after eight years at the helm (www.clinica.co.uk, 22 May 2012). Mr McLain previously served as CEO and CFO of early-stage diagnostic company Claro Scientific; before this, he held various senior management positions, including CEO, at Nabi Biopharmaceuticals (now Biota Pharmaceuticals), a biotechnology company addressing immune system conditions; and has also worked for eye care giant Bausch + Lomb.